Pharmacodynamic Study of Fibroblast Activity Protein in Patients With Localized Pancreas Cancer Undergoing Surgical Resection
OBJECTIVES:
Primary
- To assess the degree of fibroblast activation protein (FAP) enzymatic activity at the
tumor site in patients with localized pancreatic cancer.
Secondary
- To explore correlations between tumor stromal FAP enzymatic activity and stromal
α_2-antiplasmin levels.
- To explore correlations between tumor FAP enzymatic activity and plasma dipeptidyl
peptidase and plasma α_2-antiplasmin converting enzyme activity as potential
surrogates.
OUTLINE: Patients undergo fine-needle aspiration of tumor or suspected mass at baseline.
Tumor samples are analyzed by IHC for fibroblast activation protein (FAP) expression,
immunocapture assay for ex vivo FAP enzymatic activity, and western analysis for FAP
concentrations. Blood samples are collected weekly and analyzed for dipeptidyl peptidase
activity by ELISA and α_2-antiplasmin converting enzyme.
Observational
N/A
Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression
No
Jonathan Cheng, MD
Principal Investigator
Fox Chase Cancer Center
Unspecified
CDR0000579635
NCT00900016
August 2007
Name | Location |
---|---|
Fox Chase Cancer Center - Philadelphia | Philadelphia, Pennsylvania 19111-2497 |